People: Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

3.00USD
11 Jul 2014
Price Change (% chg)

$0.09 (+3.09%)
Prev Close
$2.91
Open
$2.91
Day's High
$3.04
Day's Low
$2.90
Volume
597,016
Avg. Vol
937,175
52-wk High
$7.77
52-wk Low
$1.27

Search Stocks

Grethlein, Andrew 

Brief Biography

Dr. Andrew J. Grethlein, Ph.D., is Executive Vice President - Technical Operations of Geron Corporation. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010, Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008, Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinology-oriented biopharmaceutical company. In this role, he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporation, a biotechnology company, from 1997 to 2003, including as Senior Director, South San Francisco Pharmaceutical Operations, where he had responsibility as site head for commercial manufacturing operations. From 1995 to 1997, Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a nonprofit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon's Rock Early College, his B.S. in biology from Bates College, and his M.S. and Ph.D. in chemical engineering from Michigan State University.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
103,542 -- 698,064 801,606

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Hoyoung Huh

--

John Scarlett

1,344,950

Olivia Bloom

578,818

Stephen Rosenfield

1,187,280

Andrew Grethlein

801,606

Melissa Kelly Behrs

830,707
As Of 30 Dec 2012
Search Stocks